William Wilmer, MD
Disclosures: Nothing to disclose - 08/31/2020

     Curriculum Vitae
William A. Wilmer, M.D.

Office                Kidney Specialists, Inc.

595 Copeland Mill Rd, Suite 2D Westerville, Ohio 43081

614-823-8500

Personal           Date of Birth:              April 14, 1961

Place of Birth:              Flushing, New York

Married:              Jennifer Sharp

Children:              Elizabeth, Abigail, Paige, John

Education        Wittenberg University, Springfield, OH              1979–1983

Medical College of Ohio, Toledo, OH              1984– 1988

Postgraduate Training

Internship

Department of Internal Medicine

The Ohio State University, Columbus, OH              1988 - 1989

Internal Medicine Residency

Department of Internal Medicine

The Ohio State University, Columbus, OH              1989 - 1991

Fellowship in Nephrology

Division of Nephrology

The Ohio State University, Columbus, OH              1991 - 1992

              1993- 1995

Chief Residency

Department of Internal Medicine

The Ohio State University, Columbus, OH              1992 - 1993

Appointments

Assistant Professor

Department of Internal Medicine

Division of Nephrology

The Ohio State University, Columbus, OH              1995 - 2001

Tenured Associate Professor of Medicine

Department of Internal Medicine

Division of Nephrology

The Ohio State University, Columbus, OH              2001 - 2003

Clinical Assistant Professor

Nephrology

The Ohio University College of Osteopathic Medicine              2011- present

Board Certifications and Licensure

Licensed, State of Ohio              No. 60681

Certified, American Board of Internal Medicine              1991

Re-certified              2001
Certified, American Board of Internal Medicine,

Subspecialty in Nephrology              1994

 


Re-certified              2004, 2014

             

Memberships in Professional Societies

American Society of Nephrology

International Society of Nephrology International Society of Peritoneal Dialysis Columbus Medical Association

Ohio State Medical Association

National Kidney Foundation Serving Ohio

 

Administrative Positions

Student Clerkship Director, Department of Internal Medicine              1997 - 2000
Director, Peritoneal Dialysis / Home Dialysis Program,

The Ohio State University Nephrology Division              1997 – 2003

 

Committees

College of Medicine, The Ohio State University:

Ohio State University College of Medicine Faculty Council              1997 - 2001

Med 3/ Med 4 Student Education Committee              1997 - 2000

2006 Committee Working Groups              1997 - 1999
Transition Committee, Acute Care Committee,

Ambulatory Committee

Med 3/ Med 4 Student Review Committee              1997 - 2000

Teaching and Learning Environment Task Force              1999 - 2000
Ohio State University College of Medicine

Web Task Force Committee              1998 - 1999
Department of Internal Medicine, The Ohio State University:

Medical Student Education Committee, Chairman              1997 - 2000

Medical Student Evaluation Committee              1997 - 2000

Internal Medicine Housestaff Education Committee              1995 - 2000

Intern Selection Committee              1995 - 2000

Distinguished Faculty Award Selection Committee              1997 - 2003
Division of Nephrology, The Ohio State University:

Peritoneal Dialysis Quality Assurance Committee, Director              1997 - 2003

Nephrology Division Finance Committee              1999 - 2003
Other Academic Organizations:

The Ohio Chapter of the American College of Physicians,

Student Education Committee              1997 - 2001
The Ohio State University Managed Health Care Systems

Quality Improvements Committee              2000

            Kidney Foundation Serving Ohio, Serving Ohio

                        Board member              2004-present

             Medical Advisory Board Member              2004-present
Fairfield Medical Center (Lancaster, Ohio):

Committee for Quality Improvement              2004 - 2009

Critical Care Committee              2004 - 2012

Medical Executive Committee              2011 - 2013

Dialysis Access Committee              2011 - present

Cardiovascular Institute - Committee Chairman              2011 - 2016

 

Honors and Awards

Faculty:

The Distinguished Educator Award,

The Ohio State University College of

Medicine and Public Health              1999
National Kidney Foundation of Ohio,

M.J. Cosio Research Award              1999
Ohio State University Hospitals, Patient Education

Interdisciplinary Team Award              1996

Post-graduate training:

John A. Prior Outstanding Intern Award              1989
Veterans Affairs (Columbus, Ohio)

Outstanding Resident Award              1990

Outstanding Senior Resident Award              1991

Thomas Skillman Outstanding Resident Award              1991

General Medicine Achievement Award              1993

Professional Activities

Journal Ad Hoc Reviewer:

  American Journal of Kidney Diseases

Diabetes Medicine

Journal of the American Society of Nephrology

Journal of Immunology and Immunopathology

Kidney International

American Society of Nephrology Scientific Program              1998 - 2002

Research Support

Basic Science and Applied-Basic Science Research:

National Kidney Foundation of Ohio, "The effects of high glucose on early response genes." P.I.: W. A. Wilmer, 1993– 1994 (fellowship), $ 5000 direct costs

National Kidney Foundation of Ohio, "The role of glucose on AP-1 inducible metalloproteinases." PI: W. A. Wilmer, 1994– 1995 (fellowship), $5000 direct costs

Central Ohio Diabetes Association, “High glucose effects on activator protein - 1 in human mesangial cells.” PI: W.A. Wilmer, 1995-1996, $8900, direct costs

Davis Medical Research Grant, ÒThe role of protein kinase C in glucose mediated transcription factor regulation.” PI: W.A. Wilmer, 1995– 1996, $25,000 direct costs

American Heart Association, Ohio Affiliate, “Transforming growth factor-beta one autoinduction via activator protein - 1." PI: W. A. Wilmer, 1996-1997, $58,232, direct costs

Baxter Healthcare Extramural Grant Program, “Mechanisms of fibrogenesis by human peritoneal mesothelial cells: the role of glucose, osmolality and angiotensin IIÓ PI: W. A. Wilmer, 1997– 2000, $116, 866, direct costs

American Heart Association, Ohio Affiliate, Undergraduate Student Research Fellowship, “Inhibitory effects of transforming growth factor-beta1 on activator protein-1”. PI / mentor: W.A. Wilmer, 1998, $2100 direct costs

National Kidney Foundation of Ohio, Òp38 MAPK isoform expression in human mesangial cells”, PI: W. A. Wilmer, 1999–2000, $5000, direct costs

Juvenile Diabetes Foundation International, “Growth factor activation of p38 MAPK in diabetic nephropathyÓ, PI: W. A. Wilmer, 2000–2003, $353,101 total costs

American Heart Association, Ohio Valley Affiliate Ò‘Extracellular matrix production in diabetes: The role of the p38 mitogen-activated protein kinasesÓ, PI: W.A. Wilmer,

2000 – 2002, $ 89, 831 total costs

 

 

 

 

Clinical Research:

Baxter Healthcare Corporation Renal Division: ÒA Study to Investigate the Efficacy and Safety of 7.5% Icodextrin Peritoneal Dialysis Solution as Compared to Dianeal PD-2 Peritoneal Dialysis

             Solution with 4.25% Dextrose for the Long Dwell in Patients Treated with Automated Peritoneal   

             Dialysis (APD)”

 

Publications

Peer reviewed publications:

1.             Cosio F.G., Wilmer W.A.: Effects of high glucose concentrations on c-fos: role of protein kinase C. Kidney International (1995) 48(S51 ):S1 2-17.

 

2.             Wilmer, W.A.,Tan,L.C. ,Dickerson,J.A. , Rovin, B.H.: Interleukin-1 §induction of mitogen
activated protein kinases in human mesangial cells: role of oxidation. Journal of Biological Chemistry (1997) 272(16):10877-10881.

 

3.             Wilmer, W.A., Cosio,F.G.: DNA binding of activator protein -1 isincreased in human
mesangial cells grown in high glucose environments. Kidney International (1998) 3 :1172-1181.

 

4.             Wilmer,W.A.,Cosio,F.G.,Kaumaya,P., Hugli,TE., Ember, J.: Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells. Journal of Immunology (1998)160: 5646-5652.

 

5.             Rovin,B.H., Wilmer, W. A., Danne, M., Dickerson,J.A.: The mitogen-activated protein kinase p38 is necessary for interleukin-1 §-induced monocyte chemoattractant protein-1 expression by human mesangial cells. Cytokine (1999) 11(2):118- 126.

 

6.             WilmerW.A. Hebert L.A., Lewis E.J., Rohde R.D., Whittier F., Cattran D.,LeveyA.S.,Lewis J.B. Spitalewitz S., Blumenthal S., Bain,R: Remission of the nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the Captopril Study. American Journal of Kidney Disease (1999) 34(2): 308–314.

 

7.             Baschinsky, D. Baker, P., Wilmer, W. A.: Pauci-immuneANCA-positive crescentic glomerulonephritis associated with metastatic adenocarcinoma of the lung. American Journal of Kidney Disease (2000) 36 (4): E24.

 

8.             Wimer, W.A. Dixon, C.L., Lu, L. Hilbelink, T., Rovin, B.H. Acyclopentenone prostaglandin activates mesangial MAP kinase independently of PPAR. Biochemical and Biophysical Research Communications (2001) 281:57-62.

 

9.             Wilmer, W.A., Voroshilova, O., Singh, I., Middendorf, D.F., Cosio, F.G. Transcutaneous oxygen tension in calciphylaxis patients. American Journal of Kidney Diseases, (2001) 37(4): 797-806

 

10.         Hebert L.A., Wilmer, W.A., Falkenhain, M.E., Ladson-Wofford, S.E., Nahman, N.S. Rovin, B.H.: Renoprotection: One or many therapies. Kidney International, (2001), 59: 1211-1226.

 

11.         Wilmer, W.A. Dixon, C.L., Hebert,C.: Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney International (2001), 60: 858-871.

12.            Wilmer, W.A., Pesavento, T.E., BayW.H., Middendorf, D.F, Donelan, S., Frabott,S., McElligott,R.F., Powell, S.L.: Peritoneal dialysis following failed kidney transplantation is associated with high peritoneal transport rates. Peritoneal Dialysis International (2001), 21: 411-413.

13.            Rovin, B.H. Wilmer, W.A., Lu, L., Doseff,A., Dixon, C., Kotur,M., Hilbelink,T.: The cyclopentenone
prostaglandin 1 5-Deoxy12,14-prostaglandin J2 regulates mesangial cell proliferation and death. Kidney International (2002), 61: 1293-1302.

14.            Wilmer, W.A., Magro, C.M. Calciphylaxis: Emerging concepts in prevention, diagnosis and treatment (review), Seminars in Dialysis (2002), 15(3): 172-186.

15.            Wilmer, W.A., Rovin, B.H., Hebert, C., Dixon, C.L., Lu, L. PPAR-alpha ligands inhibit H2O2- mediated activation of TGF-§1 in human mesangial cells. Antioxidants and Redox Signaling (2002), 4(6): 877–884.

16.            Agarwal,A. Wilmer, W.A. Bay, W.H. Falkenhain, M.E. Mangino, J.E. Pneumococcal and gonococcal peritonitis associated with recurrent vaginitis. Peritoneal Dialysis International (2002), 22(6): 731-732.

17.            Terrado, L.T., Wilmer,W.A., Pesavento, T.E. Culture negative PD peritonitis associated with pancreaticoduodenocystotomy leak of a pancreas transplant, American Journal of Kidney Diseases, (2003), 41(6): E4-8.

18.            Wilmer, W.A., Rovin, B.H., Hebert, C.J., Rao,S.V., Kumor, K.,Hebert, L.A., Management of            glomerular proteinuria: A commentary. J American Society of Nephrology, (2003)14(12): 3217-32.

19.            Zhang, X., Lu, L.,Dixon,C., WilmerW.A., Song,H.,Chen,X., Rvin,B.H. Stress protein activation by the cyclopentenone prostaglandin 15-Deoxy12,14-prostaglandin J2 in human mesangial cells. Kidney International (2004), 65: 798-810.

20.              Barnes, C.E., Wilmer, W.A., Hernandez, R.A., Jr., Valentine, c., Hiremath, L., Nadasdy, T.,
Satoskar,A.A., Shim, R.L., Rovin, B.H., Hebert,L.A., Relapse or worsening of nephritic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated, Nephron Clinical Practice (2011), 119:c145-c153.

Book chapters:

1.      Falkenhain, M., Wilmer, W.A. Elevated blood urea and nitrogen and serum creatinine values: acute renal failure and chronic renal failure. In Kidney Disease in Primary Care, ed. Mandel, A.K. and Nahman, N.S. Jr., Williams & Wilkins, Baltimore, 1998.

2.      Wilmer, W.A. The primary glomerulopathies, In Conn’s Current Therapy, ed. Rakel, R.E., and Bope, E., W.B. Saunders Company, Philadelphia, 2002

Abstracts (peer-reviewed, presented):

1.      Wilmer, W.A. & Cosio, F.G.: The effects of high glucose on AP-1 content in human mesangial cells. Journal of the American Society of Nephrology, (1994), 5(3):975.

2.      Cosio, F.G. & Wilmer, W.A.: Mechanisms of high glucose-induced reduction of c-fos mRNA levels in human mesangial cells. Journal of the American Society of Nephrology. (1994), 5(3): 962.

3.     Cosio F.G., Wilmer W.A.: Effects of high glucose concentrations on c-fos: role of protein kinase C. The Second Annual Hyonam Kidney Laboratory International Symposium, Seoul, Korea, 1995

4.     Wilmer W.A., Cosio F.G.: Composition and DNA-binding of activator protein - 1 (AP-1) in human mesangial cells cultured in high glucose environments. Journal of the American Society of Nephrology(1995) 6(3)1052.

5.     Wilmer W.A., Cosio F.G., Mahan J., O’Dorisio T., O’Dorisio M.S.: Elevated serum levels of substance
P in children with IgA nephropathy correlate with elevated serum IgA levels. Journal of the American Society of Nephrology (1995) 6(3): 858.

6.     Cosio F.G., Wilmer W.A., Ember J.A., Hugli T.E.: Receptors for the anaphylatoxin C5a (C5aR) on human mesangial cells. Journal of the American Society of Nephrology (1996) 7(9):826.

7.     Wilmer, W.A., Oei,S.S.: Transforming growth factor beta -1 modulates pathways involved in TPA-responsive element transcription. Journal of the American Society of Nephrology (1996) 7(9): 668.

8.     Wilmer, W.A., Dickerson,J.A.: Jun-NH2-terminal kinase (JNK) activation by protein phosphatase inhibition in human mesangial cells. Journal of the American Society of Nephrology (1997) 8:448A.

9.     Wilmer,W.A., Hebert,L.A., Lewis,E.J., et al.: Long-term follow-up of the eight patients with diabetic nephropathy who experienced remission of nephrotic syndrome during the Captopril Study. Journal of the American Society of Nephrology (1997) 8:1 20A.

10.     Donelan,S. M, Frabott,S. M., McElligott,R.F., Powell,S.L., Middendorf,D. F., Bay,W.H.,Pesavento,TE, Wilmer, W.A.: Peritoneal membrane function of patients receiving CAPD after renal allograft failure. Journal of the American Society of Nephrology (1997) 8:263A.

11.     Rovin, B. H., Wilmer,W.A., Danne, M .A., Dickerson,J .A.: p38 mitogen-activated protein
(MAP) kinase is necessary for IL-1ß-induced MCP-1 expression by human mesangial cells. Journal of the American Society of Nephrology (1997) 8:445A.

12.     Wilmer, W.A., Dixon, C.L.: Glucose-induced activation of the p38 mitogen-activated protein kinase pathway in human mesangial cells. Journal of the American Society of Nephrology (1998) 9:644A.

13.     Wilmer, W.A. Interactions between the JNK and p38 MAPK pathways during osmotic stress. Blood Purification, 17, S1 (1999): 63.

14.     Wilmer, W.A. Dixon, C.L.: High glucose concentrations activate the p38 MAPK pathway in human mesangial cells. Diabetes (1999) 48 (supp 1): A 36.

15.     Wilmer, W.A. TGF-§1 activates the p38 MAPK pathway: Implications for fibronectin regulation. Blood Purification, 18, S1 (2000): 71.

16.     Wilmer, W.A. Dixon, C.L.: High glucose and TGF-§1 activate the p38 MAPK pathway in human mesangial cells: Implications for ATF1 / CREB activation and fibronectin transcription. Journal of the American Society of Nephrology (1999)10: 692A.

17.     Wilmer, W.A. Rovin, B.H., Dixon, C.L.,Lu, L.: Peroxisome Proliferator-Activated Receptors (PPARs) induce the extracellular-regulated kinases (ERKs) in human mesangial cells (H MC), Journal of the American Society of Nephrology, (2000): 11: 436A.

18.     Wilmer, W.A. Dixon, C.L. Nahman, Jr, N.S.: The p38 MAPK pathway is necessary for TGF-§1 -mediated fibronectin production by human mesangial cells, Journal of the American Society of Nephrology, (2000): 11 :655A.

19.     Haller LU, Hebert LA, Khabiri H, Jung S, Barbosa R, Gamboa P, Natarajan K, Wilmer WA: Renal transvenous biopsy: The experience at a single U.S. center. Journal of the American Society of Nephrology, 2000)11:5A.0.             

20.     Lam, G.K., Graham, M.M., Dixon, C.L., Wilmer, W.A., Flavahan,N.A., Goldschmidt-Clermont,P.J.,

Marsh,C.B. Akt appears to have dual regulation by reactive oxygen species (ROS) and p38 to

facilitate monocyte survival: Implications in early events of atherosclerosis. Submitted to American

Heart Association (2000).

 

 

21.     Harrold, M.J., Wilmer, W.A., Mangino, J.E. and Thomas,A.: Leukocytosis and leukemoid reactions in ESRD patients with Clostridium difficile colitis: A retrospective review at a tertiary care center. Journal of the American Society of Nephrology (2001) 12: 382A.

 

22.     Wilmer, W.A., Dixon, C.L. Lu, L., Rovin B.H. J-series prostaglandins and ciglitazone inhibit TGF-§1 expression in human mesangial cells (HMC). Journal of the American Society of Nephrology (2001) 12: 720A

 

23.     Wilmer, W.A., Dixon, C.L. Antioxidants inhibit transforming growth factor-ß1 (TGF-§1) autoinduction in human mesangial cells (HMC): The role of the p38 mitogen activated protein kinase (p38 MAPK) pathway. Journal of the American Society of Nephrology. (2001) 12: 850A

 

24.     Rovin, B.H., Wilmer, W.A. Lu, L., Dixon, C.L., Doseff, A.I., Hilbelink, T. The cyclopentenone prostaglandin 1 5-deoxy-1 2,1 4-PGJ2 regulates human mesangial cell (H MC) proliferation and survival. Journal of the American Society of Nephrology. (2001) 12: 620A

 

25.     Valentine, C.W., Hebert, L.A., Rovin, B.H., Wilmer, W.A., Seth, S., Porcu, P. Anti-CD20 monoclonal antibody (Rituximab, RTX) therapy in a hemodialysis patient with severe systemic lupus erythematosis. Journal of the American Society of Nephrology, (2002) 13: 683A

 

26.     Rovin, B.H., Lu, L., Dixon, C. Wilmer, W.A., Klein, J. Mesangial expression of heat shock protein 70 in response to treatment with 15-deoxy-delta 12,14-prostaglandin J2 is a defense mechanism against cell death. Journal of the American Society of Nephrology, (2002) 13: 293A

 

27.     Ayran, M.D., Wilmer, W.A., Falkenhain, M.A., Agarwal, A.K. Magro, C.M. Painless ischemic
myopathy of calciphyalxis. Journal of the American Society of Nephrology , (2003)13: 761A.

 

28.     Hernandez, R., Wilmer, W.A., Barnes, C., Valentine, C., Nadasdy, T., Satoskar, A., Hiremath, L., Hebert, L.A. Progression of idiopathic membranous nephropathy (IMN) despite regression of immune deposits. Journal of the American Society of Nephrology, (2007) 18: 942A.

Invited Presentations

Ohio State University Department of Internal Medicine Comprehensive Board Review Course, 1995: “Malignant hypertension”

Tri-State Renal Network 9 Annual Meeting, 1996: “Dialysis adequacy”

Chillicothe Veterans Administration CME Lecture, 1996: “Nonsteroidal associated kidney disease” Ohio State University Ambulatory Teaching Seminar, 1997: “Educating residents”

Ohio State University Internal Medicine Grand Rounds, 1997: “Renoprotective strategies”

Central Ohio Diabetes Association 34th Annual Diabetes Symposium, 1997: “Diabetic kidney disease”

American Diabetes Association, Diabetic Patient Support Group Meeting, 1998: “How to prevent diabetic kidney disease”

Central Ohio Diabetes Association 36th Annual Diabetes Symposium, 1999: “Diabetic kidney disease”

Abbott Pharmaceuticals Renal Update Course, 2000: “Cytokines and the kidney”

 

University of Louisville, Nephrology Division, Research and Clinical Conferences, invited visiting faculty 2001: “Calciphylaxis” and “The role of p38 MAPKs in diabetic kidney disease”.  National Kidney Foundation of Ohio Nephrology Update Course, 2002: “Inflammatory diseases of the peritoneum in peritoneal dialysis patients”

 

National Kidney Foundation of Ohio Pharmacists Continuing Education Course, 2002: “Nonsteroidal agents and kidney disease”

Abbott Pharmaceuticals Renal Update Course, Chicago, 2002: “Diabetic nephropathy”

Ohio State University Nephrology Division CME Course on Treatment Recommendations

for Kidney Diseases in the Primary Care Office, 2003: “Hemodialysis and Peritoneal Dialysis”

National Kidney Foundation of Ohio Nephrology Update Course, 2005: “GFR Awareness”

Mount Carmel East Hospital CME, Columbus, 2005: “Chronic Kidney Disease: Identifying, Stratifying and Treatment Strategies”

National Kidney Foundation of Ohio Nephrology Update Course, 2006: “The role of Vitamin D in Chronic Kidney Disease”

National Kidney Foundation of Ohio Nephrology, 2007, “GFR Awareness: An NKF of Ohio Initiative” at Lancaster Fairfield Medical Center

Fairfield Medical Center Snider Cardiovascular Institute, 2013, “Renal Access Update: When to Initiate Dialysis”

Fairfield Medical Center ICU Update Course, 2016, “Acid-Base Disorders”

Fairfield Medical Center ICU Update Course, 2018 “ Hyponatremia”

Fairfield Medical Center ICU Update Course, 2018 “ CRRT Methods”              

National Kidney Foundation Serving Ohio, Spring Symposium, 2019  “Updated in Peritoneal Dialysis”

National Kidney Foundation Serving Ohio, Nephrology for the PCP Symposium, 2020  “ The approach to proteinuria by the PCP” .